MarketPulse
S

$SLNO

34 articles found
0 positive
34 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Class Action Over Undisclosed Safety Risks in DCCR Drug

Rosen Law Firm files securities class action against $SLNO for alleged misstatements regarding safety concerns with DCCR drug candidate for Prader-Willi syndrome treatment.
SLNOsecurities class actionlead plaintiff
BenzingaBenzinga··Law Offices Of Howard G. Smith

Soleno Therapeutics Faces Securities Fraud Suit Over DCCR Drug; Deadline Looms

Soleno Therapeutics ($SLNO) faces securities fraud lawsuit over DCCR drug for Prader-Willi syndrome. Stock plunged following safety concerns, patient death, and weak Q3 results.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Schall Law Firm

Soleno Therapeutics Faces Securities Fraud Lawsuit Over Clinical Trial Disclosures

Schall Law Firm filed securities fraud class action against $SLNO for allegedly concealing safety concerns in Phase 3 DCCR trial. Investors eligible through November 4, 2025.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Soleno Therapeutics Faces Class Action Over Undisclosed DCCR Safety Concerns

Soleno Therapeutics faces class action lawsuit alleging failure to disclose safety concerns about DCCR drug candidate from clinical trials.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Safety Risks in DCCR Drug

Soleno Therapeutics faces class action lawsuit alleging material safety concerns about DCCR drug were hidden from investors. Lead plaintiff deadline is May 5, 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Soleno Therapeutics Faces Class Action Over DCCR Safety Claims as Stock Plummets 27%

Robbins LLP launches class action against $SLNO over alleged investor deception regarding DCCR drug safety and efficacy for Prader-Willi syndrome treatment.
EOSEDRVNSLNOclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

Soleno Therapeutics Faces Securities Lawsuit Over Alleged DCCR Safety Disclosure Failures

Class action lawsuit filed against Soleno Therapeutics for allegedly failing to disclose material safety concerns about its DCCR product. Investors can apply as lead plaintiff by May 5, 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Action Against Enphase Energy Over Inventory Claims

Rosen Law Firm sued $ENPH for allegedly misleading investors on inventory management and financial prospects amid tax credit concerns.
BSXENPHSLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bernstein Liebhard Llp

Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosures

Law firm Bernstein Liebhard announces class action against $NKTR over alleged misrepresentations regarding Phase 2b trial results, affecting investors from February to December 2025.
PLUGSLNONKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Boston Scientific Faces Securities Class Action Over False Electrophysiology Claims

Rosen Law Firm files class action against $BSX over alleged false statements regarding U.S. Electrophysiology segment sustainability and concealed adverse facts.
BSXEOSESLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Nektar Therapeutics Faces Securities Class Action Over Alleged Misleading Trial Statements

Rosen Law Firm sues Nektar Therapeutics for alleged false statements about clinical trial protocols, seeking damages for injured investors as litigation moves forward.
EOSESLNONKTRsecurities class actionlead plaintiff
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Soleno Therapeutics Hit With Class Action Over VYKAT Launch Failures and Safety Disclosures

$SLNO faces securities lawsuit alleging misleading safety claims for hyperphagia drug VYKAT XR. Stock crashed 40% after short seller report and management admissions of launch disruptions.
SLNOsecurities class actionclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Soleno Therapeutics Faces Class Action Over Alleged PWS Drug Safety Misstatements

Class action lawsuit filed against $SLNO alleging false statements about DCCR safety concerns and commercial viability for Prader-Willi syndrome treatment.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Fraud Probe Over Undisclosed Safety Data

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.
SLNOstock declinesecurities class action